HAE Quote, Financials, Valuation and Earnings

Inspire Medical Systems has a net margin of 10.76% compared to Haemonetics's net margin of 1.49%. Haemonetics's return on equity of 14.16% beat Inspire Medical Systems's return on equity of 10.24%.

Haemonetics has a consensus price target of $94.30, signalling upside risk potential of 38.66%. On the other hand Inspire Medical Systems has an analysts' consensus of $213.58 which suggests that it could grow by 39.78%. Given that Inspire Medical Systems has higher upside potential than Haemonetics, analysts believe Inspire Medical Systems is more attractive than Haemonetics.

Haemonetics has a beta of 0.323, which suggesting that the stock is 67.655% less volatile than S&P 500. In comparison Inspire Medical Systems has a beta of 1.387, suggesting its more volatile than the S&P 500 by 38.691%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Inspire Medical Systems pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are larger than Inspire Medical Systems quarterly revenues of $201.3M. Haemonetics's net income of $37.5M is higher than Inspire Medical Systems's net income of $3M. Notably, Haemonetics's price-to-earnings ratio is 26.78x while Inspire Medical Systems's PE ratio is 70.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.54x versus 5.54x for Inspire Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of 10.76% compared to Haemonetics's net margin of -5.14%. Haemonetics's return on equity of 14.16% beat Integer Holdings's return on equity of 4.85%.

Haemonetics has a consensus price target of $94.30, signalling upside risk potential of 38.66%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 23.72%. Given that Haemonetics has higher upside potential than Integer Holdings, analysts believe Haemonetics is more attractive than Integer Holdings.

Haemonetics has a beta of 0.323, which suggesting that the stock is 67.655% less volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are smaller than Integer Holdings quarterly revenues of $437.4M. Haemonetics's net income of $37.5M is higher than Integer Holdings's net income of -$22.5M. Notably, Haemonetics's price-to-earnings ratio is 26.78x while Integer Holdings's PE ratio is 56.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.54x versus 2.41x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 10.76% compared to Haemonetics's net margin of 16.85%. Haemonetics's return on equity of 14.16% beat Insulet's return on equity of 43.11%.

Haemonetics has a consensus price target of $94.30, signalling upside risk potential of 38.66%. On the other hand Insulet has an analysts' consensus of $319.01 which suggests that it could grow by 22.02%. Given that Haemonetics has higher upside potential than Insulet, analysts believe Haemonetics is more attractive than Insulet.

Haemonetics has a beta of 0.323, which suggesting that the stock is 67.655% less volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are smaller than Insulet quarterly revenues of $597.5M. Haemonetics's net income of $37.5M is lower than Insulet's net income of $100.7M. Notably, Haemonetics's price-to-earnings ratio is 26.78x while Insulet's PE ratio is 44.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.54x versus 9.17x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of 10.76% compared to Haemonetics's net margin of -127.29%. Haemonetics's return on equity of 14.16% beat Staar Surgical's return on equity of -17.97%.

Haemonetics has a consensus price target of $94.30, signalling upside risk potential of 38.66%. On the other hand Staar Surgical has an analysts' consensus of $18.80 which suggests that it could fall by -3.74%. Given that Haemonetics has higher upside potential than Staar Surgical, analysts believe Haemonetics is more attractive than Staar Surgical.

Haemonetics has a beta of 0.323, which suggesting that the stock is 67.655% less volatile than S&P 500. In comparison Staar Surgical has a beta of 0.652, suggesting its less volatile than the S&P 500 by 34.797%.

Haemonetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

Haemonetics quarterly revenues are $348.5M, which are larger than Staar Surgical quarterly revenues of $42.6M. Haemonetics's net income of $37.5M is higher than Staar Surgical's net income of -$54.2M. Notably, Haemonetics's price-to-earnings ratio is 26.78x while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics is 2.54x versus 3.47x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.